Pharsight

Ukoniq is owned by Tg Theraps.

Ukoniq contains Umbralisib Tosylate.

Ukoniq has a total of 8 drug patents out of which 0 drug patents have expired.

Ukoniq was authorised for market use on 05 February, 2021.

Ukoniq is available in tablet;oral dosage forms.

Ukoniq can be used as relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy, relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen.

Drug patent challenges can be filed against Ukoniq from 2025-02-05.

The generics of Ukoniq are possible to be released after 26 May, 2035.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9150579	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)
US10570142	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)
US9969740	TG THERAPS	Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations	May, 2035 (11 years from now)
US10414773	TG THERAPS	Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations	May, 2035 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9669033	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)
US10981919	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)
US10072013	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)
US10947244	TG THERAPS	Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations	May, 2035 (11 years from now)

Do you want to check out UKONIQ patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 5, 2026

Drugs and Companies using UMBRALISIB TOSYLATE ingredient

NCE-1 date: 2025-02-05

Market Authorisation Date: 05 February, 2021

Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; Relapsed or refractory follicular lymphoma (fl) who have received at least three prior...

Dosage: TABLET;ORAL